Chest
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe COPD experience marked deterioration in lung function and breathlessness compared to patients with mild-to-moderate COPD. We report improvement of dyspnea and lung function in patients with severe COPD in the BLAZE study with QVA149, a dual bronchodilator combining the long-acting β2-agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), versus placebo and tiotropium. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, AstraZeneca, Forest Laboratories, Pfizer, Schering Plough, Grant monies (from industry related sources): GSK, Schering Plough, Methapharma, AstraZeneca, Merck Canada, Forest Laboratories, Novartis Donald Mahler: Grant monies (from industry related sources): Boehringer Ingelheim, Novartis, and Sunovion, Consultant fee, speaker bureau, advisory committee, etc.: GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion Tracy White: Employee: Novartis Pharmaceuticals Corporation Vijay Alagappan: Employee: Novartis Pharmaceuticals Corporation Hungta Chen: Employee: Novartis Pharmaceuticals Corporation Karoly Kulich: Employee: Novartis Pharma AG Nicola Gallagher: Employee: Novartis Horsham Research Centre Donald Banerji: Employee: Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Heinrich WorthClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Surgery CasesSESSION TYPE: Case ReportsPRESENTED ON: Sunday, March 23, 2014 at 09:00 AM - 10:00 AMINTRODUCTION: Cystic Fibrosis (CF) is a disease which can develop lung destruction and cause respiratory insufficiency in children. Lobar lung transplantation from adult donors has arisen as a treatment in some cases of respiratory failure in pediatric patients. ⋯ The following authors have nothing to disclose: Juan Pablo Reig, Amparo Sole, Emilio Ansótegui, Juan Escrivá, Juan Antonio PastorNo Product/Research Disclosure Information.
-
Symptoms of Respiratory Disease PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Studies of military personnel deployed to Operations Iraqi Freedom and Enduring Freedom have suggested an increase in chronic lung disease due to environmental exposures. Findings are based primarily on increased respiratory symptoms and retrospective data. Our previous study (STAMPEDE I) did not identify any acute interstitial or inflammatory process. The study objective was to complete a comprehensive evaluation of active duty military with deployment-related pulmonary symptoms and identify etiology of symptoms. ⋯ Michael Morris: Consultant fee, speaker bureau, advisory committee, etc.: Speaker Bureau for Spiriva with Pfizer/Boehringer/Ingelheim The following authors have nothing to disclose: Andrew Skabelund, Georgette Haislip, Pedro LuceroNo Product/Research Disclosure Information.
-
Asthma PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Galectins are a family of b-galactoside-binding animal lectins with functions in a variety of biological processes, including inflammation and allergic pathologies. To explore the contribution of galectins in human asthma, induced sputum samples were collected from asthma patients and healthy controls. Expression of galectin (gal)-1, gal-3 and gal-9 was analysed by flow cytometry. ⋯ The following authors have nothing to disclose: Silvia Sanchez, Rosa Girón Moreno, Rosa Gomez Punter, Emma Vazquez, Gonzalo Segrelles, Carolina Cisneros, Julio Ancochea BermúdezNo Product/Research Disclosure Information.
-
Pulmonary Hypertension Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: In the last 30 years only a few countries have gone to pursue the development of a registry in Pulmonary Artery Hypertension in which the specific characteristics of their population is evaluated and classified. In Puerto Rico this kind of information has never been collected and analyzed. Data was obtained from the only available specialized clinic in pulmonary hypertension in the island to characterize the demographics and clinical course of the Puerto Rican population and to compare individuals according to classification subgroup, treatment strategies and outcome. ⋯ The following authors have nothing to disclose: Alvaro Aranda, Elba Martin, Ricardo Fernandez, Jose Nieves, Jose Basora, Pedro TorrellasNo Product/Research Disclosure Information.